/GUTS
GUTS Stock - Fractyl Health, Inc. Common Stock
Healthcare|BiotechnologyNASDAQ
$2.20-2.65%
$0.06 (-2.65%) • Dec 19
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.92
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.41
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+263.6%upside
Target: $8.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GUTS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.18 – $2.22
TARGET (TP)$8.00
STOP LOSS$2.02
RISK/REWARD1:32.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.96
52W High$3.03
52W Low$0.82
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $93,000 | $120,000 | N/A | N/A | N/A |
| Gross Profit | $43,000 | $43,000 | $-452,000 | N/A | $-770,000 |
| Gross Margin | 46.2% | 35.8% | N/A | N/A | N/A |
| Operating Income | $-93,531,000 | $-50,836,000 | $-49,385,000 | $-36,928,000 | $-28,961,000 |
| Net Income | $-68,694,000 | $-77,091,000 | $-46,453,000 | $-38,735,000 | $-30,480,000 |
| Net Margin | -73864.5% | -64242.5% | N/A | N/A | N/A |
| EPS | $-1.62 | $-1.98 | $-1.34 | $-1.12 | $-0.86 |
Company Overview
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$14
Average Target
↑ 543.2% Upside
Now
$4
Low
$14
Average
$26
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 15th 2025 | H.C. Wainwright | Initiation | Buy | $9 |
| August 28th 2025 | Ladenburg Thalmann | Initiation | Buy | $3.6 |
| February 28th 2024 | Evercore ISI | Initiation | Outperform | - |
| February 27th 2024 | Morgan Stanley | Initiation | Overweight | $18 |
| February 27th 2024 | BofA Securities | Initiation | Buy | $26 |
Earnings History & Surprises
GUTSBeat Rate
25%
Last 8 quarters
Avg Surprise
-165.3%
EPS vs Estimate
Beats / Misses
2/5
1 met exactly
Latest EPS
$-0.35
Q4 2025
EPS Surprise History
Q2 24
-1133.8%
$-8.02vs$-0.65
Q2 24
-150.0%
$-0.75vs$-0.30
Q3 24
+21.7%
$-0.36vs$-0.46
Q4 24
+4.0%
$-0.48vs$-0.50
Q1 25
-18.2%
$-0.52vs$-0.44
Q2 25
0.0%
$-0.49vs$-0.49
Q3 25
-43.2%
$-0.53vs$-0.37
Q4 25
-2.9%
$-0.35vs$-0.34
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 2, 2026 | $-0.19 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.34 | $-0.35 | -2.9% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.37 | $-0.53 | -43.2% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.49 | $-0.49 | 0.0% | = MET |
Q1 2025 | Mar 3, 2025 | $-0.44 | $-0.52 | -18.2% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.50 | $-0.48 | +4.0% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.46 | $-0.36 | +21.7% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.30 | $-0.75 | -150.0% | ✗ MISS |
Q2 2024 | Apr 1, 2024 | $-0.65 | $-8.02 | -1133.8% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | — | $-0.33 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.63 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.25 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-0.23 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-7.54 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.26 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-0.19 | — | — |
Q4 2020 | Dec 30, 2020 | — | $-0.17 | — | — |
Q3 2020 | Sep 29, 2020 | — | $-0.16 | — | — |
Latest News
Fractyl Health Calls All 17,063,073 Warrants For Cancellation For Cash: Exercise At $1.05, If Fully Exercised Could Raise ~$17.9M
➖ NeutralBenzinga•Dec 15, 2025, 11:35 PM
FRACTYL HEALTH Director And CEO Rajagopalan Harith Purchases 10,416 Company Shares At Average Price Of $1.92/Shr
📈 PositiveBenzinga•Dec 8, 2025, 07:27 PM
HC Wainwright & Co. Reiterates Buy on Fractyl Health, Maintains $8 Price Target
📈 PositiveBenzinga•Dec 2, 2025, 05:18 PM
Fractyl Health Announces 6-Month Results From Open-Label REVEAL-1 Cohort; Upcoming Randomized 6-Month REMAIN-1 Midpoint Cohort Data Expected In January 2026
➖ NeutralBenzinga•Dec 2, 2025, 12:07 PM
Canaccord Genuity Maintains Buy on Fractyl Health, Raises Price Target to $8
📈 PositiveBenzinga•Nov 21, 2025, 06:30 PM•Also:
Fractyl Health Q3 EPS $(0.71) Misses $(0.34) Estimate. Cash And Equivalents $81.91M
📉 NegativeBenzinga•Nov 12, 2025, 09:24 PM
Fractyl Health Unveils Preclinical Results for RJVA-002, Showing 30% Weight Loss in Obesity Model
📈 PositiveBenzinga•Oct 7, 2025, 11:12 AM
Fractyl Health Files For Offering Of Up To 60M Shares Of Common Stock
➖ NeutralBenzinga•Sep 26, 2025, 09:12 PM
HC Wainwright & Co. Maintains Buy on Fractyl Health, Lowers Price Target to $8
➖ NeutralBenzinga•Sep 26, 2025, 07:15 PM
Fractyl Health shares are trading higher. The company announced the pricing of a $60 million underwritten offering of 60 million shares at $1.00 each.
📈 PositiveBenzinga•Sep 26, 2025, 06:15 PM
Fractyl Health stock gains after pricing of $60M underwritten offering
📈 PositiveSeeking Alpha•Sep 26, 2025, 11:23 AM
Fractyl Health Prices $60M Underwritten Offering Of 60M Shares At $1.00 Each
➖ NeutralBenzinga•Sep 26, 2025, 11:06 AM
Fractyl Health Study Shows Revita Helps Prevent Weight Regain After Stopping Popular GLP-1 Drugs
📈 PositiveBenzinga•Sep 26, 2025, 11:01 AM
HC Wainwright & Co. Initiates Coverage On Fractyl Health with Buy Rating, Announces Price Target of $9
📈 PositiveBenzinga•Sep 15, 2025, 11:15 AM
Ladenburg Thalmann Initiates Coverage On Fractyl Health with Buy Rating, Announces Price Target of $3.6
📈 PositiveBenzinga•Aug 28, 2025, 12:41 PM
Fractyl Health Posts 62% Wider Q2 Loss
📉 NegativeThe Motley Fool•Aug 13, 2025, 01:55 AM
Fractyl Health announces proposed public offering
➖ NeutralSeeking Alpha•Aug 5, 2025, 08:20 PM
Frequently Asked Questions about GUTS
What is GUTS's current stock price?
Fractyl Health, Inc. Common Stock (GUTS) is currently trading at $2.20 per share. The stock has moved -2.65% today.
What is the analyst price target for GUTS?
The average analyst price target for GUTS is $8.00, based on 1 analyst.
What sector is Fractyl Health, Inc. Common Stock in?
Fractyl Health, Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GUTS's market cap?
Fractyl Health, Inc. Common Stock has a market capitalization of $0.16 billion, making it a small-cap company.
Does GUTS pay dividends?
No, Fractyl Health, Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADVM
Adverum Biotechnologies, Inc.
$4.36
Mkt Cap: $0.1B
ALXO
ALX Oncology Holdings Inc.
$1.45
Mkt Cap: $0.1B
ARTV
Artiva Biotherapeutics, Inc.
$4.74
Mkt Cap: $0.1B
ATYR
aTyr Pharma, Inc.
$0.75
Mkt Cap: $0.1B
BMEA
Biomea Fusion, Inc.
$1.40
Mkt Cap: $0.1B
DTIL
Precision BioSciences, Inc.
$4.49
Mkt Cap: $0.1B
MGX
Metagenomi, Inc. Common Stock
$1.76
Mkt Cap: $0.1B
QNCX
Quince Therapeutics, Inc.
$3.57
Mkt Cap: $0.2B
RPTX
Repare Therapeutics Inc.
$2.14
Mkt Cap: $0.1B
STRO
Sutro Biopharma, Inc.
$9.98
Mkt Cap: $0.1B
Explore stocks similar to GUTS for comparison